1. Lanzkowsky Ph. Manual of pediatric hematology and oncology. 4th edition. Elseveir Inc., 2007.
2. Hoffman R, Benz E, Silberstein L et al. Hematology: Basic Principles and Practice, 6th edition. Elsevier Inc., 2013; p. 1452–68.
3. Lipshultz S, Landry D, Lopez-Mitnik G, Lipsitz S et al. Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy. J Clin Oncology 2012; 30 (10): 1050–7.
4. Bovelli D, Plataniotis G, Rolia F. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO clinical practice guidelines. Ann Oncol 2010; 21 (Suppl. 5): 277–82.
5. Khanan-Khan A, Srinivasan Sh, Czuczman M. Prevention and management of cardiotoxicity from antineoplastic therapy. J Support Oncol 2004; 2 (3): 251–66.
6. Youseff G, Links M. The prevention and management of cardiovascular complications of chemotherapy in patients with cancer. Am J Cardiovasc Drugs 2005; 5 (4): 233–43.
7. Bristow M, Thompson P, Martin R, Mason J et al. Early antthraciline cardiotixicity. Am J Med 1978; 65: 823–32.
8. Schwartz R, McKenzie W, Alexander J. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 1987; 82: 1109–18.
9. Pfeffer B, Tziros C, Katz R. Current concepts of anthracycline cardiotoxicity: pathogenesis, diagnosis and prevention. Br J Cardiol 2009; 16 (2): 85–9.
10. Cyclophosphamide. URL: http://www.ehealthme.com/cyclophosphamide
11. Fulbright J. Review of cardiotixicity in pediatric cancer patients: during and after therapy. Cardiology Research and Practice. 2011; 1: 942090. DOI:10.4061/2011/942090.
12. Review: could Cisplatin cause Myocardial infarction? URL: http://www.ehealthme.com/ds/cisplatin/myocardial+infarction
13. Steinherz L, Graham T, Hurwitz R. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Children’s Cancer Study Group. J Pediatrics 1992; 89: 942–9.
14. UK Clinical Guidelines for the Use of Adjuvant Trastuzumab (Herceptin) With or Following Chemotherapy in HER2-positive Early Breast Cancer. NCRI Breast Clinical Studies Group Clinical Studies Group. 14th December 2005. URL: http://www.dh.gov.uk/en/ Healthcare/NationalServiceFrameworks/Cancer/DH_4126383
15. Schwartz C, Hobbie W, Truesdell S et al. Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer. J Clin Oncol 1993; 11: 1906–10.
16. Schmidt B, Sreeram N, Brockmeier K. Verlängerung des QTc-Intervalls im Oberflächen-Ekg. Pädiatrische Praxis 2009; 73: 279–86.
17. Roden D, Viswanathan P. Genetics of acquired long QT syndrome. J Clin Invest 2005; 115 (8): 2025–32.
18. Mori J, Sabel A, Sagar U, Carlin S et al. Factors influencing QT prolongation in patients hospitalized with severe anorexia nervosa. Gen Hosp Psychiatry 2012; 34: 173–7.
19. Nussinovitch M, Gur E. Kaminer K, Volovitz B et al. QT variability among weight-restored patients with anorexia nervosa. Gen Hosp Psychiatry 2012; 34: 62–5.
20. Tan T, Scherrer-Crosbie M. Assesing the cardiac toxicity of chemotherapeutic agents: role of echocardiography. Curr Cardiovasc Imaging 2012; 5 (6): 403–9.
21. Plana J. Chemotherapy and the heart. Rev Esp Cardiol 2011; 64 (5): 409–15.
22. Теплякова Е.Д. Формирование кардиоваскулярных осложнений у детей с острым лимфобластным лейкозом. Автореф. дис. … д-ра мед. наук. Р. н/Д, 2012.
23. Саржевский В.О., Колесникова Д.С., Вахромеева М.Н., Мельниченко В.Я. Кардиальные тропонины и высокодозная химиотерапия с аутологичной трансплантацией при лимфомах. Гематология и трансфузиология. 2014; 1 (Прил. 1): 116.
24. Lipshultz S, Miller T, Scully R, Lipstz S et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol 2012; 30 (10): 1042–9.
25. Cardinale D, Sandri M, Colombo A et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109: 2749–54.
26. Koh E, Nakamura T, Takahashi H. Troponin-T and brain natriuretic peptide as predictors for adriamycin-induced cardiomyopathy in rats. Circulation 2004; 68: 163–7.
27. Kavey R, Allada V, Daniels S. Cardio-vascular risk reduction in high-risk pediatric patients: A scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research – Endorsed by the American Academy of Pediatric. Circulation 2006; 114: 2710–38.
28. Miller T, Lipsitz S, Lopez-Mitnik G. Characteristics and determinants of adiposity in pediatric cancer survivors. Cancer Epidemiol Biomarkers Prev 2010; 19: 2013–22.
29. Silber J, Cnaan A, Clark B et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004; 22 (5): 820–8.
30. Lee P, Mallik R. Cardiovascular rffects of radiation therapy: practical approaches to radiation therapy-induced heart disease. Cardiol Rev 2005; 13 (2): 80–6.
31. Jaworski C, Mariani Ju, Weeler G, Kaye D. Cardiac complications of thoracic irradiation. J Am Coll Cardiol 2013; 61 (23): 2319–28.
32. Brenner D, Shuryak J, Jozsef G et al. Risk and risk reduction of major coronary events associated with contemporary breast radiotherapy. JAMA Intern Med 2014; 174 (1): 158–60.

В.М.Делягин, Ю.В.Демидова, Е.А.Тихомирова

ФГБУ Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева Минздрава России, Москва